Selected research
Industry Research
Nuclear Drug for Therapeutic Industry Research Report 2026
Market perspective
The global Nuclear Drug for Therapeutic market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Nuclear Drug for Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Nuclear Drug for Therapeutic market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Nuclear Drug for Therapeutic market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Nuclear Drug for Therapeutic include Aurobindo Pharma, China Isotope & Radiation, Curium Pharmaceuticals, Dongcheng, International Isotopes, Jubilant Radiopharma, Lantheus, Mundipharma and Q BioMed, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Nuclear Drug for Therapeutic market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nuclear Drug for Therapeutic.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nuclear Drug for Therapeutic Market by Company
Aurobindo Pharma
China Isotope & Radiation
Curium Pharmaceuticals
Dongcheng
International Isotopes
Jubilant Radiopharma
Lantheus
Mundipharma
Q BioMed
Bayer
Novartis
Nuclear Drug for Therapeutic Segment by Type
Iodine-131
Radium-223
Lutetium-177
Other
Nuclear Drug for Therapeutic Segment by Application
Lymphoma
Thyroid
Bone Metastasis
Other
Nuclear Drug for Therapeutic Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Drug for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Drug for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Drug for Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nuclear Drug for Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Iodine-131
- Radium-223
- Lutetium-177
- Other
Applications
- Lymphoma
- Thyroid
- Bone Metastasis
- Other
Companies covered
- Aurobindo Pharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Dongcheng
- International Isotopes
- Jubilant Radiopharma
- Lantheus
- Mundipharma
- Q BioMed
- Bayer
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nuclear Drug for Therapeutic by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Iodine-131
- 2.2.3 Radium-223
- 2.2.4 Lutetium-177
- 2.2.5 Other
- 2.3 Nuclear Drug for Therapeutic by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Lymphoma
- 2.3.3 Thyroid
- 2.3.4 Bone Metastasis
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Nuclear Drug for Therapeutic Breakdown Data by Type
- 3.1 Global Nuclear Drug for Therapeutic Historic Market Size by Type (2021-2026)
- 3.2 Global Nuclear Drug for Therapeutic Forecasted Market Size by Type (2027-2032)
4 Nuclear Drug for Therapeutic Breakdown Data by Application
- 4.1 Global Nuclear Drug for Therapeutic Historic Market Size by Application (2021-2026)
- 4.2 Global Nuclear Drug for Therapeutic Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nuclear Drug for Therapeutic Market Perspective (2021-2032)
- 5.2 Global Nuclear Drug for Therapeutic Growth Trends by Region
- 5.2.1 Global Nuclear Drug for Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nuclear Drug for Therapeutic Historic Market Size by Region (2021-2026)
- 5.2.3 Nuclear Drug for Therapeutic Forecasted Market Size by Region (2027-2032)
- 5.3 Nuclear Drug for Therapeutic Market Dynamics
- 5.3.1 Nuclear Drug for Therapeutic Industry Trends
- 5.3.2 Nuclear Drug for Therapeutic Market Drivers
- 5.3.3 Nuclear Drug for Therapeutic Market Challenges
- 5.3.4 Nuclear Drug for Therapeutic Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nuclear Drug for Therapeutic Players by Revenue
- 6.1.1 Global Top Nuclear Drug for Therapeutic Players by Revenue (2021-2026)
- 6.1.2 Global Nuclear Drug for Therapeutic Revenue Market Share by Players (2021-2026)
- 6.2 Global Nuclear Drug for Therapeutic Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nuclear Drug for Therapeutic Head Office and Area Served
- 6.4 Global Nuclear Drug for Therapeutic Players, Product Type & Application
- 6.5 Global Nuclear Drug for Therapeutic Manufacturers Established Date
- 6.6 Global Nuclear Drug for Therapeutic Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nuclear Drug for Therapeutic Market Size (2021-2032)
- 7.2 North America Nuclear Drug for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 7.4 North America Nuclear Drug for Therapeutic Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nuclear Drug for Therapeutic Market Size (2021-2032)
- 8.2 Europe Nuclear Drug for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 8.4 Europe Nuclear Drug for Therapeutic Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nuclear Drug for Therapeutic Market Size (2021-2032)
- 9.2 Asia-Pacific Nuclear Drug for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nuclear Drug for Therapeutic Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nuclear Drug for Therapeutic Market Size (2021-2032)
- 10.2 South America Nuclear Drug for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 10.4 South America Nuclear Drug for Therapeutic Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nuclear Drug for Therapeutic Market Size (2021-2032)
- 11.2 Middle East & Africa Nuclear Drug for Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nuclear Drug for Therapeutic Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Aurobindo Pharma
- 12.1.1 Aurobindo Pharma Company Information
- 12.1.2 Aurobindo Pharma Business Overview
- 12.1.3 Aurobindo Pharma Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.1.4 Aurobindo Pharma Nuclear Drug for Therapeutic Product Portfolio
- 12.1.5 Aurobindo Pharma Recent Developments
- 12.2 China Isotope & Radiation
- 12.2.1 China Isotope & Radiation Company Information
- 12.2.2 China Isotope & Radiation Business Overview
- 12.2.3 China Isotope & Radiation Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.2.4 China Isotope & Radiation Nuclear Drug for Therapeutic Product Portfolio
- 12.2.5 China Isotope & Radiation Recent Developments
- 12.3 Curium Pharmaceuticals
- 12.3.1 Curium Pharmaceuticals Company Information
- 12.3.2 Curium Pharmaceuticals Business Overview
- 12.3.3 Curium Pharmaceuticals Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.3.4 Curium Pharmaceuticals Nuclear Drug for Therapeutic Product Portfolio
- 12.3.5 Curium Pharmaceuticals Recent Developments
- 12.4 Dongcheng
- 12.4.1 Dongcheng Company Information
- 12.4.2 Dongcheng Business Overview
- 12.4.3 Dongcheng Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.4.4 Dongcheng Nuclear Drug for Therapeutic Product Portfolio
- 12.4.5 Dongcheng Recent Developments
- 12.5 International Isotopes
- 12.5.1 International Isotopes Company Information
- 12.5.2 International Isotopes Business Overview
- 12.5.3 International Isotopes Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.5.4 International Isotopes Nuclear Drug for Therapeutic Product Portfolio
- 12.5.5 International Isotopes Recent Developments
- 12.6 Jubilant Radiopharma
- 12.6.1 Jubilant Radiopharma Company Information
- 12.6.2 Jubilant Radiopharma Business Overview
- 12.6.3 Jubilant Radiopharma Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.6.4 Jubilant Radiopharma Nuclear Drug for Therapeutic Product Portfolio
- 12.6.5 Jubilant Radiopharma Recent Developments
- 12.7 Lantheus
- 12.7.1 Lantheus Company Information
- 12.7.2 Lantheus Business Overview
- 12.7.3 Lantheus Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.7.4 Lantheus Nuclear Drug for Therapeutic Product Portfolio
- 12.7.5 Lantheus Recent Developments
- 12.8 Mundipharma
- 12.8.1 Mundipharma Company Information
- 12.8.2 Mundipharma Business Overview
- 12.8.3 Mundipharma Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.8.4 Mundipharma Nuclear Drug for Therapeutic Product Portfolio
- 12.8.5 Mundipharma Recent Developments
- 12.9 Q BioMed
- 12.9.1 Q BioMed Company Information
- 12.9.2 Q BioMed Business Overview
- 12.9.3 Q BioMed Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.9.4 Q BioMed Nuclear Drug for Therapeutic Product Portfolio
- 12.9.5 Q BioMed Recent Developments
- 12.10 Bayer
- 12.10.1 Bayer Company Information
- 12.10.2 Bayer Business Overview
- 12.10.3 Bayer Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.10.4 Bayer Nuclear Drug for Therapeutic Product Portfolio
- 12.10.5 Bayer Recent Developments
- 12.11 Novartis
- 12.11.1 Novartis Company Information
- 12.11.2 Novartis Business Overview
- 12.11.3 Novartis Revenue in Nuclear Drug for Therapeutic Business (2021-2026)
- 12.11.4 Novartis Nuclear Drug for Therapeutic Product Portfolio
- 12.11.5 Novartis Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst